ClinicalTrials.gg

Program

HD-P023

Its studies are led by Handok.

Furthest: phase 1, since Mar 20, 20243 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Handok30 open or runningphase 1since Mar 20, 2024Mar 20, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 20, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06339788 · 40 enrolled · Korea, Republic of
  2. Mar 11, 2025Phase 1 study in Healthy VolunteersNCT06889350 · 40 enrolled · South Korea
  3. Jul 30, 2025Phase 1 study in Healthy VolunteersNCT07102719 · 40 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07102719Healthy Volunteers · South Korea1CompletedOct 20, 202540
NCT06889350Healthy Volunteers · South Korea1CompletedApr 13, 202540
NCT06339788Healthy Volunteers · Korea, Republic of1CompletedJun 12, 202440

How it is read

Names in the registry

  • “HD-P023”, 3 entries

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.